Immunotherapy plus chemotherapy before surgery improves outcomes for lung cancer patients

Source: Medical Xpress

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC)—the leading cause of cancer deaths worldwide—reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

Read more